Information Provided By:
Fly News Breaks for February 19, 2016
INO
Feb 19, 2016 | 06:40 EDT
Piper Jaffray analyst Charles Duncan highlights Inovio Pharmaceuticals as the Zika virus spreads, calling the company a leader among potential vaccine players. The company's SynCon technology has a "higher than usual probability of clinical success" in Zika given its experience with other flaviviruses and tropical diseases, Duncan tells investors in a research note. He has an Overweight rating on Inovio with a $31 price target. The stock closed yesterday down 47c to $6.45.
News For INO From the Last 2 Days
There are no results for your query INO